Pharmacogenomics in Pulmonary Arterial Hypertension
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- West Penn Allegheny Health System
- Principal Investigator
- Raymond L Benza, MDAllegheny General Hospital/Allegheny-Singer Research Institute of West Penn Allegheny Health System
- Intervention
- Sitaxsentan(drug)
- Eligibility
- All sexes
- Timeline
- 2005 – 2012
Study locations (1)
- Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
Collaborators
National Institutes of Health (NIH) · Baylor College of Medicine · Emory University · University of Chicago · Johns Hopkins University · Tufts Medical Center · Sir Mortimer B. Davis - Jewish General Hospital · London Health Sciences Centre · University of Maryland, College Park · University of California, San Francisco · University of Calgary · Chest Medical Associates · Columbia University · Lung Diagnostics, Ltd. · Duke University · University of California, Los Angeles · Latter Day Saints Hospital · Louisiana State University Health Sciences Center in New Orleans · Massachusetts General Hospital · Mayo Clinic · Medical College of Wisconsin · Southeastern Lung Care · Suncoast Lung Center · Children's Hospital Colorado · University Hospitals Cleveland Medical Center · University of Colorado, Denver · University of Michigan · University of Pittsburgh Medical Center · University of Southern California · The University of Texas Medical Branch, Galveston · Vanderbilt University · Wayne State University · Ohio State University · University of Alabama at Birmingham · Washington University School of Medicine · Sentara Norfolk General Hospital · University of Texas Southwestern Medical Center · Bay Area Chest Physicians
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00593905 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07529821Additional Effects of Pilates Breathing and Diaphragmatic Breathing Combined With Moderate Intensity Continuous Treadmill Training on Blood Pressure, Chest Expansion, Pulmonary Function and Quality Of Life in Pre-hypertensive PatientsFoundation University Islamabad
- ACTIVE NOT RECRUITINGNCT07312227A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in BoliviaMassachusetts General Hospital
- ENROLLING BY INVITATIONNANCT07558460Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled TrialIstanbul University - Cerrahpasa
- RECRUITINGPHASE2NCT07318597Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)Regeneron Pharmaceuticals
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
- RECRUITINGPHASE2NCT06351345129 Xenon Imaging in Patients Treated With SotaterceptBastiaan Driehuys
- RECRUITINGPHASE4NCT07140484Sotatercept in Pulmonary Arterial HypertensionUniversity of Alberta
- RECRUITINGPHASE2NCT07175038A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)AllRock Bio, Inc.
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →